The Experts below are selected from a list of 2310 Experts worldwide ranked by ideXlab platform
Peter W De Leeuw - One of the best experts on this subject based on the ideXlab platform.
-
perindopril Indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass the picxel study
Journal of Hypertension, 2005Co-Authors: Bjorn Dahlof, Philippe Gosse, P Gueret, Olivier Dubourg, Giovanni De Simone, Roland E Schmieder, Yuri Karpov, Juan Garciapuig, Lajos Matos, Peter W De LeeuwAbstract:OBJECTIVE: Few data are available comparing the effects of monotherapy and combination therapy on target organ damage. The PICXEL study compared the efficacy of a strategy based on first-line combination with perindopril/Indapamide versus monotherapy with enalapril in reducing left ventricular hypertrophy (LVH) in hypertensive patients. METHODS: In this 1-year multicentre randomized double-blind study, patients received an increasing dosage of perindopril/Indapamide (n = 284) or enalapril (n = 272). Changes in blood pressure and echocardiographic measures of LVH were assessed from baseline to the end of treatment. Reading of the echocardiograms was central and blinded for therapy, patient and sequence. RESULTS: Systolic and diastolic blood pressure decreased significantly more in the perindopril/Indapamide than in the enalapril group (P < 0.0001 and P = 0.003). The left ventricular mass index decreased by 13.6 +/- 23.9 g/m(2) (mean +/- SD) with perindopril/Indapamide (P < 0.0001) and 3.9 +/- 23.9 g/m(2) with enalapril (P < 0.005); these decreases were significantly different (P < 0.0001). The left ventricular internal diameter, posterior and interventricular septal wall thickness decreased significantly with perindopril/Indapamide (P < or = 0.0001); the interventricular septal wall thickness decreased significantly with enalapril (P < 0.001). Both treatments were well tolerated. CONCLUSION: A strategy based on first-line combination with perindopril/Indapamide achieved better blood pressure decrease with a significantly greater degree of LVH reduction than a strategy based on monotherapy with enalapril in hypertensive patients with LVH.
-
regression of left ventricular mass in hypertensive patients treated with perindopril Indapamide as a first line combination the reason echocardiography study
American Journal of Hypertension, 2004Co-Authors: Nicola De Luca, Eoin Obrien, Jean Michel Mallion, Michael F Orourke, K H Rahn, Bruno Trimarco, Ramon Romero, Peter W De Leeuw, Gerhart Hitzenberger, Edouard BattegayAbstract:Background Increase in left ventricular mass (LVM) may be linked to morbidity and mortality in hypertensive patients. Arterial stiffness, systolic blood pressure (BP), and pulse pressure (PP) seem to be the main determinants of LVM. The perindopril/Indapamide combination normalizes systolic BP, PP, and arterial function to a greater extent than atenolol. The aim of this study was to compare the effects of perindopril (2 mg)/Indapamide (0.625 mg) first-line combination with atenolol (50 mg) on LVM reduction in hypertensive patients. Methods Two hundred fourteen patients with essential hypertension participating in the PREterax in Regression of Arterial Stiffness in a ContrOlled Double-BliNd (REASON), randomized, double-blind, parallel-group study, underwent M-mode two-dimensional-guided echocardiography. Results Perindopril/Indapamide and atenolol were both effective at brachial BP reduction during the 12-month period. The systolic BP reduction was significantly greater with perindopril/Indapamide than with atenolol (−21.2 v −15.3 mm Hg), whereas the reduction in diastolic BP was similar between treatment groups (−12.1 v −11.3 mm Hg). Reduction in LVM was higher with perindopril/Indapamide than with atenolol. The between-group difference was significant for LVM (−13.6 v −4.3 g, P = .027), LVM/body surface area (LVMI 1 , P = .032), and LVM/body height 2.7 (LVMI 2 , P = .013). The 124 patients with LV hypertrophy at baseline showed greatest LVM regression (LVM: −22.5 v −8.9 g, P = .009; LVMI 1 , P = .031; LVMI 2 , P = .028). The reduction in LVM adjusted for brachial systolic BP and heart rate was still significantly greater with perindopril/Indapamide than with atenolol. Conclusions Treatment, based on a first-line perindopril/Indapamide combination in hypertensive patients, was more effective than atenolol on regression of echocardiographic indices of LVM and LV hypertrophy.
-
twenty four hour ambulatory blood pressure monitoring efficacy of perindopril Indapamide first line combination in hypertensive patients the reason study
American Journal of Hypertension, 2004Co-Authors: Jean Michel Mallion, Eoin Obrien, Michael F Orourke, K H Rahn, Peter W De Leeuw, Bernard Chamontin, Roland Asmar, Daniel Duprez, Ramon RomeroAbstract:Abstract Background Circadian blood pressure (BP) measurements provide more information on hypertensive complications than office BP measurements. The purpose of this study was to analyze the efficacy of the first-line combination of perindopril 2 mg plus Indapamide 0.625 mg versus atenolol 50 mg on BP parameters and variability over 24 h in patients with hypertension. Methods A double-blind, randomized, controlled, 12-month study comparing perindopril/Indapamide and atenolol was performed in 201 patients (age 55.0 years) with uncomplicated sustained essential hypertension. Ambulatory BP measurements (ABPM) were done every 15 min over 24 h. Results After 1 year of treatment, the decrease in systolic BP was significantly greater for perindopril/Indapamide than for atenolol during the entire 24-h period (-13.8 v −9.2 mm Hg), the daytime and the nighttime periods (P Conclusions The perindopril/Indapamide first-line combination decreased SBP and PP more effectively than atenolol. Moreover, the BP control effect was smooth and consistent throughout the 24-h dosing interval and BP reduction variability was lower than the one induced by atenolol.
-
regression of left ventricular hypertrophy in hypertensive patients treated with Indapamide sr 1 5 mg versus enalapril 20 mg the live study
Journal of Hypertension, 2000Co-Authors: Philippe Gosse, Peter W De Leeuw, P Gueret, Olivier Dubourg, Yuri Karpov, Desmond John Sheridan, Faiez Zannad, Joseluis Palmagamiz, Achille C Pessina, Wolfgang MotzAbstract:ObjectiveTo compare the efficacy of Indapamide sustained release (SR) 1.5 mg and enalapril 20 mg at reducing left ventricular mass index (LVMI) in hypertensive patients with left ventricular hypertrophy (LVH).DesignThe LIVE study (left ventricular hypertrophy regression, Indapamide versus enalapril)
Jean Michel Mallion - One of the best experts on this subject based on the ideXlab platform.
-
regression of left ventricular mass in hypertensive patients treated with perindopril Indapamide as a first line combination the reason echocardiography study
American Journal of Hypertension, 2004Co-Authors: Nicola De Luca, Eoin Obrien, Jean Michel Mallion, Michael F Orourke, K H Rahn, Bruno Trimarco, Ramon Romero, Peter W De Leeuw, Gerhart Hitzenberger, Edouard BattegayAbstract:Background Increase in left ventricular mass (LVM) may be linked to morbidity and mortality in hypertensive patients. Arterial stiffness, systolic blood pressure (BP), and pulse pressure (PP) seem to be the main determinants of LVM. The perindopril/Indapamide combination normalizes systolic BP, PP, and arterial function to a greater extent than atenolol. The aim of this study was to compare the effects of perindopril (2 mg)/Indapamide (0.625 mg) first-line combination with atenolol (50 mg) on LVM reduction in hypertensive patients. Methods Two hundred fourteen patients with essential hypertension participating in the PREterax in Regression of Arterial Stiffness in a ContrOlled Double-BliNd (REASON), randomized, double-blind, parallel-group study, underwent M-mode two-dimensional-guided echocardiography. Results Perindopril/Indapamide and atenolol were both effective at brachial BP reduction during the 12-month period. The systolic BP reduction was significantly greater with perindopril/Indapamide than with atenolol (−21.2 v −15.3 mm Hg), whereas the reduction in diastolic BP was similar between treatment groups (−12.1 v −11.3 mm Hg). Reduction in LVM was higher with perindopril/Indapamide than with atenolol. The between-group difference was significant for LVM (−13.6 v −4.3 g, P = .027), LVM/body surface area (LVMI 1 , P = .032), and LVM/body height 2.7 (LVMI 2 , P = .013). The 124 patients with LV hypertrophy at baseline showed greatest LVM regression (LVM: −22.5 v −8.9 g, P = .009; LVMI 1 , P = .031; LVMI 2 , P = .028). The reduction in LVM adjusted for brachial systolic BP and heart rate was still significantly greater with perindopril/Indapamide than with atenolol. Conclusions Treatment, based on a first-line perindopril/Indapamide combination in hypertensive patients, was more effective than atenolol on regression of echocardiographic indices of LVM and LV hypertrophy.
-
twenty four hour ambulatory blood pressure monitoring efficacy of perindopril Indapamide first line combination in hypertensive patients the reason study
American Journal of Hypertension, 2004Co-Authors: Jean Michel Mallion, Eoin Obrien, Michael F Orourke, K H Rahn, Peter W De Leeuw, Bernard Chamontin, Roland Asmar, Daniel Duprez, Ramon RomeroAbstract:Abstract Background Circadian blood pressure (BP) measurements provide more information on hypertensive complications than office BP measurements. The purpose of this study was to analyze the efficacy of the first-line combination of perindopril 2 mg plus Indapamide 0.625 mg versus atenolol 50 mg on BP parameters and variability over 24 h in patients with hypertension. Methods A double-blind, randomized, controlled, 12-month study comparing perindopril/Indapamide and atenolol was performed in 201 patients (age 55.0 years) with uncomplicated sustained essential hypertension. Ambulatory BP measurements (ABPM) were done every 15 min over 24 h. Results After 1 year of treatment, the decrease in systolic BP was significantly greater for perindopril/Indapamide than for atenolol during the entire 24-h period (-13.8 v −9.2 mm Hg), the daytime and the nighttime periods (P Conclusions The perindopril/Indapamide first-line combination decreased SBP and PP more effectively than atenolol. Moreover, the BP control effect was smooth and consistent throughout the 24-h dosing interval and BP reduction variability was lower than the one induced by atenolol.
-
twenty four hour antihypertensive efficacy of Indapamide 1 5 mg sustained release results of two randomized double blind controlled studies
Journal of Cardiovascular Pharmacology, 1998Co-Authors: Jean Michel Mallion, Roland Asmar, Sophie Boutelant, David GuezAbstract:The antihypertensive efficacy of a 1.5-mg sustained-release formulation (SR 1.5) of Indapamide, a diuretic related to thiazide, has been pointed out by using conventional sphygmomanometric measurement 24 h after dosing in clinic, in two large European randomized, double-blind, controlled studies (2 and 3 months). One of these studies was then extended to 12 months, as a complementary open study. Quality-controlled ambulatory blood pressure monitoring (ABPM) data for a total of 216 patients from these studies are presented, including subgroups of hypertensives and responders. Indapamide SR 1.5 achieves an adequate 24-h blood pressure control by significantly reducing the 24-h, diurnal, and nocturnal blood pressures versus baseline, confirming the sphygmomanometric data. The benefit at 2 and 3 months is maintained at 1 year, which confirms the long-term efficacy of SR 1.5 mg. The trough-to-peak ratio--not previously calculated for a diuretic according to international guidelines--meets Food and Drug Administration requirements and confirms the 24-h efficacy of Indapamide SR 1.5.
Roland Asmar - One of the best experts on this subject based on the ideXlab platform.
-
blood pressure lowering efficacy and safety of perindopril Indapamide amlodipine single pill combination in patients with uncontrolled essential hypertension a multicenter randomized double blind controlled trial
Journal of Hypertension, 2017Co-Authors: Jeanjacques Mourad, Celso Amodeo, Martine De Champvallins, Romualda Brzozowskavillatte, Roland AsmarAbstract:This 4-month, double-blind, randomized, controlled trial was designed to demonstrate the superiority of perindopril/Indapamide/amlodipine single pill over perindopril/Indapamide after 1 month and to determine further up-titration efficacy and safety in patients with mild-to-moderate hypertension. After a 1-month run-in period on perindopril/Indapamide 5/1.25 mg, patients with SBP/DBP at least 150/95 mmHg and no diabetes or renal insufficiency received perindopril/Indapamide/amlodipine 5/1.25/5 mg single pill or continued on the same treatment. At 1, 2, and 3 months, patients with uncontrolled blood pressure (SBP/DBP ≥ 140/90 mmHg) were gradually up-titrated with a higher dose of the triple therapy up to perindopril/Indapamide/amlodipine 10/2.5/10 mg in both groups. Efficacy was assessed on office supine SBP (main criterion) and DBP, blood pressure control, and response rates. Treatment effect on ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM) parameters was also assessed in two subpopulations of 276 and 263 patients, respectively. A total of 454 hypertensive patients (diabetes and renal insufficiency excluded) were randomized, 227 to each group (56% were men, mean age was 55 years, blood pressure 162.3/101.1 mmHg). After 1 month, superior SBP (−3.1 mmHg, P = 0.02) and DBP (−2.8 mmHg, P < 0.001) reductions were observed with perindopril/Indapamide/amlodipine, which were even more pronounced after excluding white-coat effect in the sustained hypertension population (−5.3/−3.7 mmHg). Similar results were observed in terms of blood pressure response (72 vs. 53%, P < 0.0001) and control rates (32 vs. 25%, P = 0.005). Up-titration was effective at each visit in both treatment arms (P < 0.001). Both ABPM and HBPM results confirmed the superiority of the triple therapy at 1 month on ASBP/ADBP and HSBP/HDBP: −4.5/−2.0 mmHg for ABPM (P < 0.001/P = 0.04), and −4.9/−3.1 mmHg for HBPM (both, P < 0.001). Up-titration steps resulted in further significant decreases in both ABPM and HBPM. Both treatment regimens were well tolerated regarding adverse events or laboratory testing. In particular, peripheral edema known to be amlodipine dose dependent, appeared in only a few cases, none with the highest dose. Hypotension, orthostatic hypotension, and cough whatever the dose were infrequent. There were no treatment-related serious adverse events. Perindopril/Indapamide/amlodipine in a single pill produces superior reductions in blood pressure compared with dual therapy. Triple therapy up-titration was well tolerated and effective leading to BP control rates of over 80%. Analysis of 24-h ABPM and HBPM results corroborated these findings.
-
twenty four hour ambulatory blood pressure monitoring efficacy of perindopril Indapamide first line combination in hypertensive patients the reason study
American Journal of Hypertension, 2004Co-Authors: Jean Michel Mallion, Eoin Obrien, Michael F Orourke, K H Rahn, Peter W De Leeuw, Bernard Chamontin, Roland Asmar, Daniel Duprez, Ramon RomeroAbstract:Abstract Background Circadian blood pressure (BP) measurements provide more information on hypertensive complications than office BP measurements. The purpose of this study was to analyze the efficacy of the first-line combination of perindopril 2 mg plus Indapamide 0.625 mg versus atenolol 50 mg on BP parameters and variability over 24 h in patients with hypertension. Methods A double-blind, randomized, controlled, 12-month study comparing perindopril/Indapamide and atenolol was performed in 201 patients (age 55.0 years) with uncomplicated sustained essential hypertension. Ambulatory BP measurements (ABPM) were done every 15 min over 24 h. Results After 1 year of treatment, the decrease in systolic BP was significantly greater for perindopril/Indapamide than for atenolol during the entire 24-h period (-13.8 v −9.2 mm Hg), the daytime and the nighttime periods (P Conclusions The perindopril/Indapamide first-line combination decreased SBP and PP more effectively than atenolol. Moreover, the BP control effect was smooth and consistent throughout the 24-h dosing interval and BP reduction variability was lower than the one induced by atenolol.
-
twenty four hour antihypertensive efficacy of Indapamide 1 5 mg sustained release results of two randomized double blind controlled studies
Journal of Cardiovascular Pharmacology, 1998Co-Authors: Jean Michel Mallion, Roland Asmar, Sophie Boutelant, David GuezAbstract:The antihypertensive efficacy of a 1.5-mg sustained-release formulation (SR 1.5) of Indapamide, a diuretic related to thiazide, has been pointed out by using conventional sphygmomanometric measurement 24 h after dosing in clinic, in two large European randomized, double-blind, controlled studies (2 and 3 months). One of these studies was then extended to 12 months, as a complementary open study. Quality-controlled ambulatory blood pressure monitoring (ABPM) data for a total of 216 patients from these studies are presented, including subgroups of hypertensives and responders. Indapamide SR 1.5 achieves an adequate 24-h blood pressure control by significantly reducing the 24-h, diurnal, and nocturnal blood pressures versus baseline, confirming the sphygmomanometric data. The benefit at 2 and 3 months is maintained at 1 year, which confirms the long-term efficacy of SR 1.5 mg. The trough-to-peak ratio--not previously calculated for a diuretic according to international guidelines--meets Food and Drug Administration requirements and confirms the 24-h efficacy of Indapamide SR 1.5.
Ioan Tomuta - One of the best experts on this subject based on the ideXlab platform.
-
high throughput nir chemometric methods for determination of drug content and pharmaceutical properties of Indapamide tablets
Journal of Pharmaceutical and Biomedical Analysis, 2013Co-Authors: Ioan Tomuta, Lucia Maria Rus, Rares Iovanov, Luca Liviu RusAbstract:Abstract This paper describes the development, validation and application of NIR-chemometric methods for API content and pharmaceutical characterization (disintegration time and crushing strength) of Indapamide intact tablets. Development of the method for chemical characterization was performed on samples corresponding to 80, 90, 100, 110 and 120% of Indapamide content and for pharmaceutical characterization on samples prepared at nine different compression forces (covering the interval 7–45 kN). NIR spectra of prepared tablets were recorded in transmission mode, and partial least-squares followed by leave-one-out cross-validation were used to develop models for the prediction of the drug content and the pharmaceutical properties of tablets. All developed models were validated in terms of trueness, precision and accuracy. No statistical differences were found between results predicted by NIR-chemometric methods and the ones determined by reference methods. Therefore, the developed NIR-chemometric methods meet the requirements of a high-throughput method for the determination of drug content, pharmaceutical properties of Indapamide tablets.
-
High-throughput NIR-chemometric methods for determination of drug content and pharmaceutical properties of Indapamide powder blends for tabletting
Journal of Pharmaceutical and Biomedical Analysis, 2012Co-Authors: Alina Porfire, Lucia Rus, Andreea Loredana Vonica, Ioan TomutaAbstract:This paper describes the development and application of NIR-chemometric methods for active content assay and pharmaceutical characterization (granulometric analysis and flowability assessment) of Indapamide powder blends for tabletting. Indapamide powder blends were prepared and their NIR spectra were recorded in reflectance mode. Partial least-squares (PLS) regression followed by leave-one-out cross-validation was used to develop calibration models for predicting the Indapamide content and pharmaceutical properties. The method for Indapamide assay was validated in terms of trueness, precision, accuracy. The near infrared based property predictions were compared with the reference method results and no significant differences were found between the reference and predicted characteristics. The developed NIR-chemometric methods can be useful tools for prediction of active content, granulometric properties and parameters related to flowability of pharmaceutical powders.
Ramon Romero - One of the best experts on this subject based on the ideXlab platform.
-
regression of left ventricular mass in hypertensive patients treated with perindopril Indapamide as a first line combination the reason echocardiography study
American Journal of Hypertension, 2004Co-Authors: Nicola De Luca, Eoin Obrien, Jean Michel Mallion, Michael F Orourke, K H Rahn, Bruno Trimarco, Ramon Romero, Peter W De Leeuw, Gerhart Hitzenberger, Edouard BattegayAbstract:Background Increase in left ventricular mass (LVM) may be linked to morbidity and mortality in hypertensive patients. Arterial stiffness, systolic blood pressure (BP), and pulse pressure (PP) seem to be the main determinants of LVM. The perindopril/Indapamide combination normalizes systolic BP, PP, and arterial function to a greater extent than atenolol. The aim of this study was to compare the effects of perindopril (2 mg)/Indapamide (0.625 mg) first-line combination with atenolol (50 mg) on LVM reduction in hypertensive patients. Methods Two hundred fourteen patients with essential hypertension participating in the PREterax in Regression of Arterial Stiffness in a ContrOlled Double-BliNd (REASON), randomized, double-blind, parallel-group study, underwent M-mode two-dimensional-guided echocardiography. Results Perindopril/Indapamide and atenolol were both effective at brachial BP reduction during the 12-month period. The systolic BP reduction was significantly greater with perindopril/Indapamide than with atenolol (−21.2 v −15.3 mm Hg), whereas the reduction in diastolic BP was similar between treatment groups (−12.1 v −11.3 mm Hg). Reduction in LVM was higher with perindopril/Indapamide than with atenolol. The between-group difference was significant for LVM (−13.6 v −4.3 g, P = .027), LVM/body surface area (LVMI 1 , P = .032), and LVM/body height 2.7 (LVMI 2 , P = .013). The 124 patients with LV hypertrophy at baseline showed greatest LVM regression (LVM: −22.5 v −8.9 g, P = .009; LVMI 1 , P = .031; LVMI 2 , P = .028). The reduction in LVM adjusted for brachial systolic BP and heart rate was still significantly greater with perindopril/Indapamide than with atenolol. Conclusions Treatment, based on a first-line perindopril/Indapamide combination in hypertensive patients, was more effective than atenolol on regression of echocardiographic indices of LVM and LV hypertrophy.
-
twenty four hour ambulatory blood pressure monitoring efficacy of perindopril Indapamide first line combination in hypertensive patients the reason study
American Journal of Hypertension, 2004Co-Authors: Jean Michel Mallion, Eoin Obrien, Michael F Orourke, K H Rahn, Peter W De Leeuw, Bernard Chamontin, Roland Asmar, Daniel Duprez, Ramon RomeroAbstract:Abstract Background Circadian blood pressure (BP) measurements provide more information on hypertensive complications than office BP measurements. The purpose of this study was to analyze the efficacy of the first-line combination of perindopril 2 mg plus Indapamide 0.625 mg versus atenolol 50 mg on BP parameters and variability over 24 h in patients with hypertension. Methods A double-blind, randomized, controlled, 12-month study comparing perindopril/Indapamide and atenolol was performed in 201 patients (age 55.0 years) with uncomplicated sustained essential hypertension. Ambulatory BP measurements (ABPM) were done every 15 min over 24 h. Results After 1 year of treatment, the decrease in systolic BP was significantly greater for perindopril/Indapamide than for atenolol during the entire 24-h period (-13.8 v −9.2 mm Hg), the daytime and the nighttime periods (P Conclusions The perindopril/Indapamide first-line combination decreased SBP and PP more effectively than atenolol. Moreover, the BP control effect was smooth and consistent throughout the 24-h dosing interval and BP reduction variability was lower than the one induced by atenolol.
